Our Relationship with HIF-1α; its Complicated 766 Words | 3 Min Read The human body has an intricate relationship with the naturally occurring protein HIF-1α, which is vital for life, but imbalances in its expression can result in life-threatening conditions. HIF-1α,...
Business Buzz
National Rare Disease Heart Disease
Heart Disease 1014 Words | 4 Min Read At N1, our purpose is to restore lives and make a positive impact on the people we serve. Therefore, we prioritize the well-being of those we share this world with and have a social contract with the world that reflects our...
National Rare Disease Day: Neurological Disease
Neurological Disease 993 Words | 4 min Read At N1, our purpose is to restore lives and make a positive impact on the people we serve. Therefore, we prioritize the well-being of those we share this world with and have a social contract with the world that reflects our...
National Rare Disease Day: Pulmonary Diseases
Pulmonary Diseases 963 Words | 3.8 minute Read At N1, our purpose is to restore lives and make a positive impact on the people we serve. Therefore, we prioritize the well-being of those we share this world with and have a social contract with the world that reflects...
Eroom’s Law or a Technopreneur in King Pharma’s Court: Part 3
A Technopreneur Lens 895 words | 3.2 minute read In Musing 1 we explored the foundation of Eroom’s Law. In Musing 2 we pirouetted our way through author reflections a decade after publication, dusted with contrasting views on trends in the cost of Drug Discovery...
Eroom’s Law or a Technopreneur in King Pharma’s Court: Part 2
Reverberation 577 words | 1.8 minute read In “The First Steps” Musing 1 we traveled Eroom’s Law, introduced in a 2012 piece for Nature Reviews Drug Discovery titled “Diagnosing the decline in pharmaceutical R&D efficiency”. Source Immense transformations in...
Eroom’s Law or a Technopreneur in King Pharma’s Court: Part 1
The First Steps 625 words | 2.1 minute read One Billion Dollars Because it was grassy and wanted wear A billion dollars doesn’t go as far in drug commercialization as it once did. Or does it? Arguments tilt each way, but it is well-defined that in seasons when...